Literature DB >> 11899264

Chronic tendon pain: no signs of chemical inflammation but high concentrations of the neurotransmitter glutamate. Implications for treatment?

Håkan Alfredson1, Ronny Lorentzon.   

Abstract

Chronic musculo-tendinous pain syndromes are relatively common and associated with very high socio-economic costs. Their aetiology and pathogenesis are still unknown. In the athletic population, chronic tendon pain is most often seen among recreational male and female athletes in the age group between 30-60 years, and is considered to be associated with overuse of the aged tendon. Treatment is known to be difficult. In general, these chronic painful conditions have been considered to include an inflammatory component, and the nomenclature used (tendinitis, tendonitis) most often implies an inflammatory involvement. Despite that tendon biopsies have shown an absence of inflammatory cell infiltration, anti-inflammatory agents (NSAID'S, corticosteroidal injections) are most often included in the treatment. Our research has been focused on chronic painful conditions in the Achilles-, patellar-, and extensor carpi radialis brevis (ECRB)-tendons. We have demonstrated, for the first time, that it is possible to use the microdialysis technique for in vivo investigations of human tendons, and that the excitatory neurotransmitter glutamate exists in human tendons. We have identified and measured the concentrations of prostaglandin E2 (PGE2) in tendons as well. The results showed that chronic painful tendinosis (Achilles-, patellar-, ECRB-) had significantly higher concentrations of glutamate, but not PGE2, as compared to the pain-free normal tendons. With the use of immunohistochemical analyses and enzyme histochemistry of human Achilles- and patellar tendon biopsies, we have also, for the first time demonstrated that glutamate NMDARI-immunoreaction was present in nerve structures. These findings altogether, indicate that glutamate might be involved in chronic tendon pain, and further emphasizes that there is no chemical inflammation (normal PGE2 levels) in the chronic stage of these relatively common so-called tendinopathies. The findings of glutamate and it's NMDARI-receptors might have implications for treatment and be a potential target for drugs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11899264     DOI: 10.2174/1389450023348028

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  33 in total

Review 1.  Glutamate pharmacology and metabolism in peripheral primary afferents: physiological and pathophysiological mechanisms.

Authors:  Kenneth E Miller; E Matthew Hoffman; Mathura Sutharshan; Ruben Schechter
Journal:  Pharmacol Ther       Date:  2011-01-26       Impact factor: 12.310

2.  A randomised, placebo controlled trial of low level laser therapy for activated Achilles tendinitis with microdialysis measurement of peritendinous prostaglandin E2 concentrations.

Authors:  J M Bjordal; R A B Lopes-Martins; V V Iversen
Journal:  Br J Sports Med       Date:  2006-01       Impact factor: 13.800

3.  Group II metabotropic glutamate receptor activation attenuates peripheral sensitization in inflammatory states.

Authors:  J Du; S Zhou; S M Carlton
Journal:  Neuroscience       Date:  2008-04-16       Impact factor: 3.590

4.  Ketamine attenuates glutamate-induced mechanical sensitization of the masseter muscle in human males.

Authors:  Brian E Cairns; Peter Svensson; Kelun Wang; Eduardo Castrillon; Steen Hupfeld; Barry J Sessle; Lars Arendt-Nielsen
Journal:  Exp Brain Res       Date:  2005-11-16       Impact factor: 1.972

5.  [Tendinopathy of the tibialis anterior tendon : surgical management].

Authors:  H Waizy; F Goede; C Plaass; C Stukenborg-Colsman
Journal:  Orthopade       Date:  2011-07       Impact factor: 1.087

6.  CURRENT CONCEPTS IN THE TREATMENT OF PATELLAR TENDINOPATHY.

Authors:  Mark F Reinking
Journal:  Int J Sports Phys Ther       Date:  2016-12

7.  Physiotherapy alone or in combination with corticosteroid injection for acute lateral epicondylitis in general practice: a protocol for a randomised, placebo-controlled study.

Authors:  Morten Olaussen; Øystein Holmedal; Morten Lindbaek; Søren Brage
Journal:  BMC Musculoskelet Disord       Date:  2009-12-04       Impact factor: 2.362

8.  The prevalence of neovascularity in patients clinically diagnosed with rotator cuff tendinopathy.

Authors:  Jeremy S Lewis; Syed A Raza; James Pilcher; Christine Heron; Jan D Poloniecki
Journal:  BMC Musculoskelet Disord       Date:  2009-12-21       Impact factor: 2.362

9.  Long lasting pain hypersensitivity following ligation of the tendon of the masseter muscle in rats: a model of myogenic orofacial pain.

Authors:  Wei Guo; Hu Wang; Shiping Zou; Feng Wei; Ronald Dubner; Ke Ren
Journal:  Mol Pain       Date:  2010-07-15       Impact factor: 3.395

Review 10.  The basic science of tendinopathy.

Authors:  Yinghua Xu; George A C Murrell
Journal:  Clin Orthop Relat Res       Date:  2008-05-14       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.